Exclusive: Novartis pitches discounts on pricey gene therapy for deadly muscle disorder
LOS ANGELES/ZURICH (Reuters) – Novartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy (SMA), a treatment that could cost more than a million dollars, but the gesture comes with strings attached. FILE PHOTO: Swiss drugmaker Novartis’ logo is seen at the company’s plant in… Read More »